Concepedia
Statistics
Publications
51
Citations
3.9K
H-Index
32
Active since
1981
Affiliations
Centre for Cancer Biology(Current)
GlaxoSmithKline (United Kingdom)
New Frontier
Molecular Discovery (United Kingdom)
Loughborough University
David Haigh is an author at Centre for Cancer Biology specializing in organic chemistry, medicinal chemistry, and chemistry.
Publications per year
1981–2014
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription
Matthew P. Coghlan, Ainsley A. Culbert, Darren A.E. Cross et al. · Chemistry & Biology · 2000 · 895 citations · Full text
Life Sciences, Biochemistry, Molecular Biology +11
[[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents
Barrie C. C. Cantello, Michael A. Cawthorne, Graham P. Cottam et al. · Journal of Medicinal Chemistry · 1994 · 266 citations
Natural Sciences, Medicinal Chemistry, Pharmacology +7
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
Paul Young, Derek R. Buckle, Barrie C. C. Cantello et al. · PubMed · 1998 · 230 citations
Medicine, Endocrinology, Pharmacology +17
Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population.
H. J. Bodansky, Anthony Staines, C. R. Stephenson et al. · BMJ · 1992 · 202 citations · Full text
Medicine, Endocrinology, Pediatrics +17
3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)
David G. Smith, Marianne Buffet, Ashley Fenwick et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 160 citations · Full text
Life Sciences, Biochemistry, Medicinal Chemistry +9
1–5 of 51